Indices of oxidative stress in Parkinson’s disease, Alzheimer’s disease and dementia with Lewy bodies

  • A. D. Owen
  • A. H. V. Schapira
  • P. Jenner
  • C. D. Marsden
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 51)


The cause of neuronal cell death in Parkinson’s disease is unknown but there is accumulating evidence suggesting that oxidative stress may be involved in this process. Current evidence shows that in the substantia nigra there is altered iron metabolism, decreased levels of reduced glutathione and an impairment of mitochondrial complex I activity. However, these changes seem to be unique to the substantia nigra and have not been found in other areas of the brain known to be altered in Parkinson’s disease, such as substantia innominata. In addition they do not appear to be related to the presence of Lewy bodies, as other areas of the brain containing Lewy bodies do not show evidence of either oxidative stress or mitochondrial dysfunction. Oxidative stress has now been demonstrated in Alzheimer’s disease and its presence appears to be correlated with regions of marked pathological changes.


Substantia Nigra Multiple System Atrophy Lewy Body Dementia With Lewy Body Substantia Innominata 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in post-mortem parkinsonian brain. Lancet ii: 219–220.Google Scholar
  2. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389.PubMedCrossRefGoogle Scholar
  3. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in the brain in Parkinson’s disease. J Neurochem 52: 1830–1836.PubMedCrossRefGoogle Scholar
  4. Dexter DT, Carayon A, Vidaillhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD (1990) Decreased ferritin levels in brain in Parkinson’s disease. J Neurochem 55: 16–20.PubMedCrossRefGoogle Scholar
  5. Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60: 273–281.PubMedGoogle Scholar
  6. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel S, Lees AJ, Schapira AHV, Jenner P, Marsden CD (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy Body disease. Ann Neurol 35: 38–44.PubMedCrossRefGoogle Scholar
  7. Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796–798.PubMedCrossRefGoogle Scholar
  8. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AHV (1994) Complex I, iron and ferritin in Parkinson’s disease substantia nigra. Ann Neurol 36: 876–881.PubMedCrossRefGoogle Scholar
  9. Mastrogiacomo F, Bergeron C, Kish SJ (1993) Brain α-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. J Neurochem 61: 2007–2014.PubMedCrossRefGoogle Scholar
  10. Mecocci P, MacGarvey U, Flint-Beal M (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 36: 747–751.PubMedCrossRefGoogle Scholar
  11. Mizuno Y, Matsuda S, Yoshina H, Mori H, Hattori N (1994) An immunohistochemical study of α-ketoglutarate dehydrogenase complex in Parkinson’s disease. Ann Neurol 35: 204–210.PubMedCrossRefGoogle Scholar
  12. Palmer AM, Burns MA (1994) Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer’s disease. Brain Res 645: 338–342.PubMedCrossRefGoogle Scholar
  13. Parker WD, Parks JK (1995) Cytochrome c oxidase in Alzheimer’s disease brain: purification and characterization. Neurol 45: 482–486.CrossRefGoogle Scholar
  14. Perry T, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 33: 305–310.PubMedCrossRefGoogle Scholar
  15. Perry E, McKeith I, Perry R (1996) Dementia with Lewy bodies: clinical, pathological and treatment issues. Cambridge University Press.CrossRefGoogle Scholar
  16. Reiderer P, Sofie E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinson’s disease. J Neurochem 52: 381–389.CrossRefGoogle Scholar
  17. Sanchezramos JR, Overvik E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson’s disease brain. Neurodegeneration 3: 197–204.Google Scholar
  18. Schapira AHV, Cooper JM, Dexter DT, Clark JB, Jenner P, Marsden CD (1990a) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54: 823–827.PubMedCrossRefGoogle Scholar
  19. Schapira AHV, Mann VM, Cooper JM, Dexter DT, Daniel SE, Jenner P, Clark JB, Marsden CD (1990b) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 55: 2142–2145.PubMedCrossRefGoogle Scholar
  20. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 36: 348–355.PubMedCrossRefGoogle Scholar
  21. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson’s disease. Ann Neurol 36: 356–361.PubMedCrossRefGoogle Scholar
  22. Sofic E, Reiderer P, Heinsen, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • A. D. Owen
    • 1
  • A. H. V. Schapira
    • 2
    • 3
  • P. Jenner
    • 1
  • C. D. Marsden
    • 3
  1. 1.Neurodegenerative Disease Research Centre, Pharmacology GroupBiomedical Sciences Division, King’s CollegeLondonUK
  2. 2.Department of Clinical NeurosciencesRoyal Free Hospital Medical SchoolLondonUK
  3. 3.University Department of Clinical NeurologyInstitute of Neurology, National Hospital for Neurology and NeurosurgeryLondonUK

Personalised recommendations